Jehison Alirio Herrera-Pulido1,2, Orlando Ricaurte Guerrero3, Jinneth Acosta Forero3, Pablo Moreno-Acosta1,4, Alfredo Romero-Rojas5, Carolina Sanabria1, Gustavo Hernández6, Martha Lucía Serrano1,7. 1. Cancer Biology Research Group, National Cancer Institute, Bogotá, Colombia. 2. Master's Program in Human Genetics, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia. 3. Department of Pathology, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia. 4. Clinical, Molecular and Cellular Radiobiology Research Group, National Cancer Institute, Bogotá, Colombia. 5. Oncological Pathology Group, National Cancer Institute, Bogotá, Colombia. 6. Public Health and Cancer Epidemiology Group, National Cancer Institute, Bogotá, Colombia. 7. Chemistry Department, Faculty of Sciences, Universidad Nacional de Colombia, Bogotá, Colombia.
Abstract
BACKGROUND/AIM: Although some mutations of KRAS proto-oncogene, GTPase (KRAS) have been associated with the prognosis and therapeutic management of colorectal cancer (CRC), the epigenetic mechanisms (DNA methylation and microRNA expression) that regulate wild-type KRAS expression in patients with CRC are poorly known. The aim of this study was to establish whether there is a relationship between the expression of the wild-type KRAS gene, the methylation status of its distal promoter, and miR-143 and miR-18a-3p levels in samples of sporadic CRC. PATIENTS AND METHODS: A total of 51 cases of sporadic CRC with wild-type KRAS were analyzed. The expression levels of KRAS mRNA, miR-18a-3p, miR-143, and KRAS protein, as well as methylation in the distal promoter of the KRAS gene were evaluated. RESULTS: In the analyzed cases, KRAS mRNA expression was detected in 51.1%; wild-type KRAS protein was found in the membrane in 31.4% and in the cytoplasm in 98% of cases. An inverse relationship of marginal significance was observed between miR-18a-3p and KRAS protein expression in the cytoplasm (odds ratio=0.14, 95% confidence interval=0.012-1.092; p=0.08). The methylation status of the distal promoter of KRAS at four CpG islands was analyzed in 30 cases (58.8%): partial methylation of the four CpG islands evaluated was observed in two cases (6.7%). In these cases, KRAS protein expression was not evidenced at the membrane level; miR-18a-3p expression was not detected either but high expression of miR-143 was observed. CONCLUSION: No association was found between the expression levels of KRAS mRNA, miR-18a-3p, miR-143 and methylation status. Methylation status was detected with low frequency, thus being the first report of methylation in wild-type KRAS. Copyright 2022, International Institute of Anticancer Research.
BACKGROUND/AIM: Although some mutations of KRAS proto-oncogene, GTPase (KRAS) have been associated with the prognosis and therapeutic management of colorectal cancer (CRC), the epigenetic mechanisms (DNA methylation and microRNA expression) that regulate wild-type KRAS expression in patients with CRC are poorly known. The aim of this study was to establish whether there is a relationship between the expression of the wild-type KRAS gene, the methylation status of its distal promoter, and miR-143 and miR-18a-3p levels in samples of sporadic CRC. PATIENTS AND METHODS: A total of 51 cases of sporadic CRC with wild-type KRAS were analyzed. The expression levels of KRAS mRNA, miR-18a-3p, miR-143, and KRAS protein, as well as methylation in the distal promoter of the KRAS gene were evaluated. RESULTS: In the analyzed cases, KRAS mRNA expression was detected in 51.1%; wild-type KRAS protein was found in the membrane in 31.4% and in the cytoplasm in 98% of cases. An inverse relationship of marginal significance was observed between miR-18a-3p and KRAS protein expression in the cytoplasm (odds ratio=0.14, 95% confidence interval=0.012-1.092; p=0.08). The methylation status of the distal promoter of KRAS at four CpG islands was analyzed in 30 cases (58.8%): partial methylation of the four CpG islands evaluated was observed in two cases (6.7%). In these cases, KRAS protein expression was not evidenced at the membrane level; miR-18a-3p expression was not detected either but high expression of miR-143 was observed. CONCLUSION: No association was found between the expression levels of KRAS mRNA, miR-18a-3p, miR-143 and methylation status. Methylation status was detected with low frequency, thus being the first report of methylation in wild-type KRAS. Copyright 2022, International Institute of Anticancer Research.
Entities:
Keywords:
DNA methylation; KRAS; colorectal cancer; miR-143; miR-18a-3p
Authors: Malte Schmick; Nachiket Vartak; Björn Papke; Marija Kovacevic; Dina C Truxius; Lisaweta Rossmannek; Philippe I H Bastiaens Journal: Cell Date: 2014-04-10 Impact factor: 41.582
Authors: Z Zhang; Y Wang; H G Vikis; L Johnson; G Liu; J Li; M W Anderson; R C Sills; H L Hong; T R Devereux; T Jacks; K L Guan; M You Journal: Nat Genet Date: 2001-09 Impact factor: 38.330
Authors: Caroline Roost; Stephen R Lynch; Pedro J Batista; Kun Qu; Howard Y Chang; Eric T Kool Journal: J Am Chem Soc Date: 2015-02-02 Impact factor: 15.419
Authors: Ondrej Fiala; Ondrej Sorejs; Petr Hosek; Vaclav Liska; Ondrej Vycital; Jan Bruha; Radek Kucera; Ondrej Topolcan; Jindrich Finek; Diana Maceckova; Pavel Pitule Journal: Cancer Genomics Proteomics Date: 2020 Sep-Oct Impact factor: 4.069